The Efficacy of Treating Patients with Serotonin Reuptake Inhibitors

363 Words1 Page
A recent study examined the efficacy of treating patients with serotonin reuptake inhibitors (SSRIs) who are suffering from Major Depressive Disorder (MDD), or who are comorbid for MDD and Posttraumatic Stress Disorder (PTSD) (Sher et al., 2012). Even though SSRIs are recommended for treating these conditions, previous research findings suggested that SSRIs might be less effective for patients comorbid for MDD and PTSD. Several self-reporting instruments were used, including the Beck Depression Inventory (BDI). The BDI has been extensively tested since it was first designed by Aaron T. Beck in 1961, and has proven to be both valid and reliable (Encyclopedia of Medical Disorders, 2012). The study recruited 96 patients with MDD for the study, of which 20 were comorbid for MDD and PTSD (Sher et al., 2012). BDI scores were determined before and after three months of SSRI treatment. Patients with MDD alone went from a mean BDI score of 25.5 (moderate depression) to 15.3 (mild depression) with treatment, while patients comorbid with MDD and PTSD went from a mean BDI score of 28.7 (almost severe depression) to 15.2. The difference between these two groups were not statistically significant, either before (p = 0.41) or after treatment (p = 0.97). The BDI failed to detect a greater improvement in suicidal ideation for patients suffering from MDD and PTSD, which was revealed by the Beck Scale for Suicidal Ideation. These results suggest that SSRI treatment is equally effective in
Open Document